| | |
| Clinical data | |
|---|---|
| Drug class | Catechol O-methyltransferase inhibitor |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H12N2O2 |
| Molar mass | 264.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Neluxicapone (INN ) is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024. [1] [2] [3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone. [4] [3] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease. [4] Neluxicapone was first described in the literature by 2018. [3] [1] Its INN was designated by the World Health Organization (WHO) in 2019. [2]
-capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66)